Therapeutic approaches to inflammation in neurodegenerative disease

Current Opinion in Neurology

Volumn 20, Issue 3, 2007, Pages 351-357

  Klegeris, Andis ^a   McGeer, Edith G ^a   McGeer, Patrick L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

synuclein; Microglia; Neuroinflammation; NSAIDs; Parkinson's disease

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA SYNUCLEIN; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; CANNABINOID RECEPTOR; CD14 ANTIGEN; CHEMOKINE RECEPTOR CXCR1; CXCL1 CHEMOKINE; DOPAMINE; ESTROGEN; ETANERCEPT; FRACTALKINE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMATE RECEPTOR ANTAGONIST; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLIXIMAB; INTERLEUKIN 1BETA; MINOCYCLINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICERGOLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; QUINONE DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ASTROCYTE; DEGENERATIVE DISEASE; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; GENETIC ANALYSIS; HUMAN; INFLAMMATION; MICROGLIA; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ALPHA-SYNUCLEIN; BRAIN; ENCEPHALITIS; GLIOSIS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MICROGLIA; PARKINSON DISEASE; RECEPTORS, CYTOKINE;

EID: 34248400478     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3280adc943     Document Type: Review

References (65)

1. Boillee S, Van de Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006; 52:39-59.
2. Cagnin A, Kassiou M, Meikle SR, Banati RB. In vivo evidence for microglial activation in neurodegenerative dementia. Acta Neurol Scand 2006; 114 (Suppl. 185):107-114.
3. Griffin WS. Inflammation and neurodegenerative diseases. Am J Clin Nutr 2006; 83 (Suppl.):480S-484S.
4. Hoozemans JJ, Veerhuis R, Rozemuller JM, Eikelenboom P. Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology. Int J Dev Neurosci 2006; 24:157-165.
5. Kim YS, Joh TH. Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Exp Mol Med 2006; 38:333-347. This is a comprehensive review of microglial function and its control in physiological conditions as well as under pathological conditions of Parkinson's disease.
6. McGeer PL, Rogers J, McGeer EG. Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J Alzheimers Dis 2006; 9 (Suppl.3):271-276.
7. Sastre M, Klockgether T, Heneka MT. Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int J Dev Neurosci 2006; 24:167-176.
8. Wersinger C, Sidhu A. An inflammatory pathomechanism for Parkinson's disease? Curr Med Chem 2006; 13:591-602. This is a comprehensive review of the current knowledge on neuroinflammatory mechanisms in Parkinson's disease.
9. Zipp F, Aktas O. The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci 2006; 29:518-527. In this review authors analyse how different initial triggers, including autoimmune (e.g. multiple sclerosis), infectious or non-inflammatory (i.e. ischaemic or degenerative), may lead to activation of common neuroinflammatory pathways resulting in neurotoxicity.
10. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988; 38:1285-1291.
11. Liu B. Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease. AAPS J 2006; 8:E606-E621. This is a summary of current knowledge on microglial and astrocyte activation in various animal models of Parkinson's disease and the proposed anti-inflammatory strategies aimed at inhibiting microglial activation.
12. McLaughlin P, Zhou Y, Ma T, et al. Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity. Glia 2006; 53:567-582. A comparison of microglial proteomes from two mouse strains, C57BL/6 and SWR/J, which demonstrated striking differences in the extent of dopaminergic neurodegeneration induced by a parkinsonian toxicant MPTP.
13. Sawada M, Imamura K, Nagatsu T. Role of cytokines in inflammatory process in Parkinson's disease. J Neural Transm Suppl 2006; 70:373-381. The authors discuss their previous human immunohistochemical data on microglial activation in Parkinson's disease and propose a model where activated microglia may be functionally either neuroprotective or neurotoxic depending on the stimuli they encounter.
14. Langston JW, Forno LS, Tetrud J, et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999; 46:598-605.
15. McGeer PL, Schwab C, Parent A, Doudet D. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine administration. Ann Neurol 2003; 54:599-604.
16. Ruano D, Revilla E, Gavilan MP, et al. Role of p38 and inducible nitric oxide synthase in the in vivo dopaminergic cells' degeneration induced by inflammatory processes after lipopolysaccharide injection. Neuroscience 2006; 140:1157-1168.
17. Miklossy J, Doudet DD, Schwab C, et al. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Exp Neurol 2006; 197:275-283.
18. Ishida Y, Nagai A, Kobayashi S, Kim SU. Upregulation of protease-activated receptor-1 in astrocytes in Parkinson disease: astrocyte-mediated neuroprotection through increased levels of glutathione peroxidase. J Neuropathol Exp Neurol 2006; 65:66-77.
19. Min KJ, Yang MS, Kim SU, et al. Astrocytes induce hemeoxygenase-1 expression in microglia: a feasible mechanism for preventing excessive brain inflammation. J Neurosci 2006; 26:1880-1887.
20. Shih AY, Fernandes HB, Choi FY, et al. Policing the police: astrocytes modulate microglial activation [comment]. J Neurosci 2006; 26:3887-3888.
21. Goldknopf IL, Sheta EA, Bryson J, et al. Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson's disease. Biochem Biophys Res Commun 2006; 342:1034-1039.
22. Fonteh AN, Harrington RJ, Huhmer AF, et al. Identification of disease markers in human cerebrospinal fluid using lipidomic and proteomic methods. Dis Markers 2006; 22:39-64.
23. Bower JH, Maraganore DM, Peterson BJ, et al. Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study. Neurology 2006; 67:494-496.
24. Lin JJ, Chen CH, Yueh KC, et al. A CD14 monocyte receptor polymorphism and genetic susceptibility to Parkinson's disease for females. Parkinsonism Relat Disord 2006; 12:9-13.
25. Chen H, Jacobs E, Schwarzschild MA, et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 2005; 58:963-967.
26. Chen H, Zhang SM, Hernan MA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003; 60:1059-1064.
27. Hernan MA, Logroscino G, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology 2006; 66:1097-1099. This prospective study of more than 1200 Parkinson's disease cases and more than 6600 controls shows that nonaspirin NSAID use is associated with a higher risk of Parkinson's disease in women but a lower risk in men.
28. McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging 2006; May 10 [Epub ahead of print].
29. Asanuma M, Miyazaki I. Nonsteroidal anti-inflammatory drugs in Parkinson's disease: possible involvement of quinone formation. Expert Rev Neurotherapeutics 2006; 6:1313-1325. This is a comprehensive review of possible COX-independent actions of NSAIDs in Parkinson's disease with a special emphasis on the effects of this class of drugs on dopamine quinone formation.
30. Ho L, Qin W, Stetka BS, Pasinetti GM. Is there a future for cyclo-oxygenase inhibitors in Alzheimer's disease? CNS Drugs 2006; 20:85-98. A comprehensive review of the possible COX-dependent as well as COX-independent actions of NSAIDs in Alzheimer's disease.
31. Klegeris A, McGeer PL. Nonsteroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. Curr Alzheimer Res 2005; 2:355-365.
32. Maharaj H, Maharaj DS, Daya S. Acetylsalicylic acid and acetaminophen protect against MPP+-induced mitochondrial damage and superoxide anion generation. Life Sci 2006; 78:2438-2443.
33. Kurkowska-Jastrzebska I, Czlonkowski A, Czlonkowska A. Ibuprofen and the mouse model of Parkinson's disease. Ann Neurol 2006; 59:988-989.
34. Wallace JL. Nitric oxide, aspirin-triggered lipoxins and NO-aspirin in gastric protection. Inflamm Allergy Drug Targets 2006; 5:133-137.
35. Dahan A, Hoffman A. Mode of administration dependent uptake of indomethacin: sustained systemic input increases brain influx. Drug Metab Dispos 2007; 35:321-324.
36. Dvir E, Friedman JE, Lee JY, et al. A novel phospholipid derivative of indomethacin, DP-155 [mixture of 1-steroyl and 1-palmitoyl-2-{4-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetamido]butanoyl}-sn-glycero-3-phosophatidyl choline], shows superior safety and similar efficacy in reducing brain amyloid β in an Alzheimer's disease model. J Pharmacol Exp Ther 2006; 318:1248-1256.
37. Cho BP, Song DY, Sugama S, et al. Pathological dynamics of activated microglia following medial forebrain bundle transection. Glia 2006; 53:92-102.
38. Kim YS, Choi DH, Block ML, et al. A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. FASEB J 2007; 21:179-187. This study demonstrated that the active form of matrix metalloproteinase-3 is released by stressed dopaminergic cells, and that it causes microglia to become neurotoxic both in vitro and in vivo.
39. Kalkonde YV, Morgan WW, Sigala J, et al. Chemokines in the MPTP model of Parkinson's disease: Absence of CCL2 and its receptor CCR2 does not protect against striatal neurodegeneration. Brain Res 2007; 1128:1-11.
40. Ubogu EE, Cossoy MB, Ransohoff RM. The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol Sci 2006; 27:48-55.
41. Chen K, Huang J, Gong W, et al. CD40/CD40L dyad in the inflammatory and immune responses in the central nervous system. Cell Mol Immunol 2006; 3:163-169.
42. Okuno T, Nakatsuji Y, Kumanogoh A, et al. Loss of dopaminergic neurons by the induction of inducible nitric oxide synthase and cyclooxygenase-2 via CD 40: relevance to Parkinson's disease. J Neurosci Res 2005; 81:874-882.
43. Klegeris A, Pelech S, Giasson BI, et al. α-Synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiol Aging 2006; Dec 11 [Epub ahead of print]. Human microglial neurotoxicity is shown to be induced by α-synuclein and its disease-causing mutated forms. Phosphoproteomics analyses indicate involvement of MAP kinases. Presence of cell surface receptors for α-synuclein is suggested.
44. Zhang W, Wang T, Pei Z, et al. Aggregated α-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 2005; 19:533-542.
45. Klegeris A, Giasson BI, Zhang H, et al. Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in astrocytes and astrocytoma cells. FASEB J 2006; 20:2000-2008. This describes the first study to show that α-synuclein and its disease-causing mutated forms stimulate human astrocytes. Presence of cell surface receptors for α-synuclein is suggested.
46. Re DB, Przedborski S. Fractalkine: moving from chemotaxis to neuroprotection [comment]. Nature Neurosci 2006; 9:859-861.
47. Cardona AE, Pioro EP, Sasse ME, et al. Control of microglial neurotoxicity by the fractalkine receptor. Nature Neurosci 2006; 9:917-924. Three different in-vivo models of CNS injury are used to show that excessive activation occurs in microglia deficient for the fractalkine receptor CX3CR1. IL-1β is implicated as the molecule responsible for the ensuing neurotoxicity.
48. Streit WJ, Davis CN, Harrison JK. Role of fractalkine (CX3CL1) in regulating neuron-microglia interactions: development of viral-based CX3CR1 antagonists. Curr Alzheimer Res 2005; 2:187-189.
49. Bernardo A, Minghetti L. PPAR-γ agonists as regulators of microglial activation and brain inflammation. Curr Pharm Des 2006; 12:93-109.
50. Drew PD, Xu J, Storer PD, et al. Peroxisome proliferator-activated receptor agonist regulation of glial activation: relevance to CNS inflammatory disorders. Neurochem Int 2006; 49:183-189.
51. Lehrke M, Lazar MA. The many faces of PPARγ. Cell 2005; 123:993-999.
52. Sundararajan S, Jiang Q, Heneka M, Landreth G. PPARγ as a therapeutic target in central nervous system diseases. Neurochem Int 2006; 49:136-144.
53. Qian L, Block ML, Wei SJ, et al. Interleukin-10 protects lipopolysaccharide-induced neurotoxicity in primary midbrain cultures by inhibiting the function of NADPH oxidase. J Pharmacol Exp Ther 2006; 319:44-52.
54. McCoy MK, Martinez TN, Ruhn KA, et al. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J Neurosci 2006; 26:9365-9375.
55. Mizuno T, Kuno R, Nitta A, et al. Protective effects of nicergoline against neuronal cell death induced by activated microglia and astrocytes. Brain Res 2005; 1066:78-85.
56. Sriram K, Miller DB, O'Callaghan JP. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-α. J Neurochem 2006; 96:706-718.
57. Takeuchi H, Jin S, Wang J, et al. Tumor necrosis factor-α induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J Biol Chem 2006; 281:21362-21368. This study showed that TNFa in an autocrine manner induces microglial release of glutamate via connexin 32 hemichannel of the gap junction. It is suggested that hemichannel blockers and glutaminase inhibitors could be used to reduce neuronal death in various neurodegenerative disorders.
58. Vally M, Seenu S, Pillarisetti S. Emerging peptide therapeutics for inflammatory diseases. Curr Pharm Biotechnol 2006; 7:241-246. This is an up-to-date summary of anti-inflammatory peptides currently under development as biological anti-inflammatory drugs by various biotech and pharmaceutical companies.
59. Ralay Ranaivo H, Craft JM, Hu W, et al. Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. J Neurosci 2006; 26:662-670.
60. Ryu JK, Choi HB, McLarnon JG. Peripheral benzodiazepine receptor ligand PK11195 reduces microglial activation and neuronal death in quinolinic acid-injected rat striatum. Neurobiol Dis 2005; 20:550-561.
61. Tripanichkul W, Sripanichkulchai K, Finkelstein DI. Estrogen down-regulates glial activation in male mice following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication. Brain Res 2006; 1084:28-37.
62. Eljaschewitsch E, Witting A, Mawrin C, et al. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 2006; 49:67-79.
63. Sarkar D, Fisher PB. Molecular mechanisms of aging-associated inflammation. Cancer Lett 2006; 236:13-23.
64. Golde TE. 'Magic' bullets, shotguns or cocktails to treat or prevent Alzheimer's disease. In: Jucker M, Beyreuther K, Haass C, Nitsch R, Christen Y, editors. Alzheimer: 100 years and beyond. Berlin: Springer-Verlag; 2006. pp. 431-433.
65. Marchetti B, Abbracchio MP. To be or not to be (inflamed): is that the question in anti-inflammatory drug therapy of neurodegenerative disorders? Trends Pharmacol Sci 2005; 26:517-525.